Janssen publishes positive safety and efficacy data for single-dose COVID-19 vaccine

Janssen has published positive data from the Phase 3 studies of its single-dose COVID-19 vaccine candidate, showing it to be 66% effective overall in preventing coronavirus in participants.

Join OnMedica and benefit from:

  • Bitesize CPD and easy to digest content, free for UK-based GPs and specialist doctors
  • High-quality, evidence-based content developed by expert editors and clinicians
  • Articles, quizzes, videos, visual summaries and more
  • Regulatory alerts and round-up of medical journals
  • New content added daily, so you know you’re always up to date

Existing members Sign in